Get started
NNN

NEXTCELL PHARMA AB

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

NXTCL fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

NextCell Pharma AB engages in the development of stem cell products. It specializes in the treatment of diabetes and immunosuppression in kidney transplants. The company was founded by Mathias Svahn, Edvard Smith, Hans-Peter Torsten Ekre, and Lena Degling Wilkingsson on March 19, 2014 and is headquartered in Huddinge, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

NXTCL does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company